Novartis AG vs Oklo Inc — how do they compare? Novartis AG trades at $152.4 (market cap $295.37B), while Oklo Inc trades at $47.47 (market cap $8.74B). The key difference: Novartis AG is far larger — about 33.8× Oklo Inc's market cap, and Novartis AG pays a 3.07% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.
| NVS | OKLO | |
|---|---|---|
Market Cap | $295.37B | $8.74B |
Sector | Health | Technology |
52-Week High | $168.62 | $174.14 |
52-Week Low | $119.31 | $36.84 |
Enterprise Value | $336.69B | $6.28B |
Dividend Yield | 3.07% | — |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →